CoChat

Cardiovascular Benefits of GLP-1-BasedTherapies in Patients with Diabetes Mellitus Type 2: Effects on Endothelial and Vascular Dysfunction beyond Glycemic Control

Open access
Forst, Thomas, Weber, Matthias M., Pfützner, Andreas · 2012 · Experimental Diabetes Research

The DOI matches its Crossref record; 91 of the 91 references it cites were found in a registry or an index.

Abstract

Type 2 diabetes mellitus (T2DM) is a progressive multisystemic disease accompanied by vascular dysfunction and a tremendous increase in cardiovascular mortality. Numerous adipose-tissue-derived factors and beta cell dysfunction contribute to the increased cardiovascular risk in patients with T2DM. Nowadays, numerous pharmacological interventions are available to lower blood glucose levels in patients with type 2 diabetes. Beside more or less comparable glucose lowering efficacy, some of them have shown limited or probably even unfavorable effects on the cardiovascular system and overall mortality. Recently, incretin-based therapies (GLP-1 receptor agonists and DPP-IV inhibitors) have been introduced in the treatment of T2DM. Beside the effects of GLP-1 on insulin secretion, glucagon secretion, and gastrointestinal motility, recent studies suggested a couple of direct cardiovascular effects of GLP-1-based therapies. The goal of this paper is to provide an overview about the current knowledge of direct GLP-1 effects on endothelial and vascular function and potential consequences on the cardiovascular outcome in patients with T2DM treated with GLP-1 receptor agonists or DPP-IV inhibitors.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1155/2012/635472

Cites

91 of 91 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Schematic illustration of the central role of visceral adipose tissue in the generation of the atherogenic environment in obese patients. Visceral adipose tissue induces insulin resistance, thereby increasing insulin and proinsulin release from the beta cell. Unphysiological levels of insulin and proinsulin promote atherogenesis through the activation of endothelial MAPK. Preadipocytes secrete numerous adipocytokines involved in the pathogenesis of hypertension, dyslipidemia, and inflammation. (MAPK: mitogen-activated protein kinase, IL-6: interleukin-6, TNFα: tumor necrosis factor α, FFA: free fatty acids).
Figure 1 Schematic illustration of the central role of visceral adipose tissue in the generation of the atherogenic environment in obese patients. Visceral adipose tissue induces insulin resistance, thereby increasing insulin and proinsulin release from the beta cell. Unphysiological levels of insulin and proinsulin promote atherogenesis through the activation of endothelial MAPK. Preadipocytes secrete numerous adipocytokines involved in the pathogenesis of hypertension, dyslipidemia, and inflammation. (MAPK: mitogen-activated protein kinase, IL-6: interleukin-6, TNFα: tumor necrosis factor α, FFA: free fatty acids).CC BY · PubMed Central
Figure 2 Schematic illustration of intracellular insulin signalling (aPKC: atypical Protein-Kinase C, eNOS: endothelial Nitric Oxide Synthase, ET1: Endothelin 1, FOX01: Forkhead Box01, IRS: Insulin Receptor Substrate, MAPK: Mitogen Activated Proteinkinase, MEK: Mitogen Activated Proteinkinase Kinase, NO: Nitric Oxide, PDK: Phosphoinositide-Dependent Kinase, PI3K: Phosphatidylinostol 3 Kinase, RAS, RAF: Proto-Oncogenes, SHC: Adapter Protein; adapted to [6]).
Figure 2 Schematic illustration of intracellular insulin signalling (aPKC: atypical Protein-Kinase C, eNOS: endothelial Nitric Oxide Synthase, ET1: Endothelin 1, FOX01: Forkhead Box01, IRS: Insulin Receptor Substrate, MAPK: Mitogen Activated Proteinkinase, MEK: Mitogen Activated Proteinkinase Kinase, NO: Nitric Oxide, PDK: Phosphoinositide-Dependent Kinase, PI3K: Phosphatidylinostol 3 Kinase, RAS, RAF: Proto-Oncogenes, SHC: Adapter Protein; adapted to [6]).CC BY · PubMed Central
Figure 3 Postprandial proinsulin/insulin ratio in patients treated with sulfonylurea, insulin Glargine, or DPP-IV inhibitors compared to nondiabetic healthy controls (*: P < 0.05 versus nondiabetic controls adapted to [67]).
Figure 3 Postprandial proinsulin/insulin ratio in patients treated with sulfonylurea, insulin Glargine, or DPP-IV inhibitors compared to nondiabetic healthy controls (*: P < 0.05 versus nondiabetic controls adapted to [67]).CC BY · PubMed Central
Figure 4 Schematic illustration of GLP-1-receptor-dependent and GLP-1-receptor-independent pathways in the signalling of GLP-1 associated cardiovascular effects (PI3K: phosphatidylinositol 3 kinase; cAMP: cyclic adenosine monophosphate, PKA: protein kinase A, PKB: protein kinase B, GSK3ß: glycogen synthase kinase 3 beta, MEK1/2: components of the MAP kinase cascade, ERK: extracellular-signal-regulated kinase, NO: nitric oxide, eNOS: endothelial nitric oxide synthase, cGMP: cyclic guanosine monophosphate, PKG: protein kinase G; adapted to [69]).
Figure 4 Schematic illustration of GLP-1-receptor-dependent and GLP-1-receptor-independent pathways in the signalling of GLP-1 associated cardiovascular effects (PI3K: phosphatidylinositol 3 kinase; cAMP: cyclic adenosine monophosphate, PKA: protein kinase A, PKB: protein kinase B, GSK3ß: glycogen synthase kinase 3 beta, MEK1/2: components of the MAP kinase cascade, ERK: extracellular-signal-regulated kinase, NO: nitric oxide, eNOS: endothelial nitric oxide synthase, cGMP: cyclic guanosine monophosphate, PKG: protein kinase G; adapted to [69]).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

1 retracted

Show all 91 references

Research works printed but not linked: 4

  1. 2005, Panminerva Medica, 47, 201
  2. 10.1185/030079907X253870 · doi:10.1185/030079907x253870 · Paper page
  3. 1993, American Journal of Physiology, 265, L374
  4. 2009, European Heart Journal, 30, 917

Cited by

Metadata

Authors
Forst, T., Weber, M. M., & Pfützner, A.
Affiliations
  • Johannes Gutenberg University Mainz (DE)
  • Institute for Clinical Research and Development, 55116 Mainz, Germany
Corresponding author
Forst, Thomas
Venue
Experimental Diabetes Research
Published
2012
Volume
2012
Pages
1-9
ISSN
  • 1687-5214 (ISSN-L)
  • 1687-5303
OpenAlex
W2102467882
Cited by
44
References
91
Citations by year
2026: 2 · 2025: 5 · 2024: 2 · 2023: 2 · 2022: 2 · 2021: 1 · 2020: 3 · 2019: 1 · 2018: 1 · 2017: 4 · 2016: 5 · 2015: 6 · 2014: 2 · 2013: 6 · 2012: 2
FWCI
0.70
Type
journal article
Language
en
Open access
Locations
  • Experimental Diabetes Research (publishedVersion, cc-by)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
Funders
  • Eli Lilly and Company
  • Novo Nordisk
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Disease and Adiposity
Keywords
type 2 diabetes, GLP-1 receptor agonists, DPP-4 inhibitors, incretin-based therapy, endothelial dysfunction, vascular dysfunction, cardiovascular risk, cardiovascular mortality, beta-cell dysfunction
MeSH terms
Blood Glucose, Body Weight, Diabetes Mellitus, Type 2, Diabetic Angiopathies, Endothelium, Vascular, Humans, Hypoglycemic Agents, Glucagon-Like Peptide 1, Dipeptidyl-Peptidase IV Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.